On August 6th, BBM-H90 1 injection independently developed by Shanghai Xinzhi Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Faith Medicine, an innovative gene therapy company, was approved by the National Pharmaceutical Products Supervision and Administration (NMPA) for drug clinical trials, and will officially start to register for clinical trials.

This is the first AAV gene therapy drug for hemophilia that has been approved to enter the registered clinical trial in China, and it is also the first gene therapy drug for rare diseases that is systematically administered in China. BBM-H90 1 injection is an AAV gene therapy drug, which is suitable for preventing bleeding in adult male hemophilia B.